Source: U.S. Department of Defense
Publication Date: May 31, 2017
The Department of Defense (DoD) published an article discussing the military pursuit into disease prevention and vaccines, as U.S. service members deploy to areas rife with infectious diseases, such as malaria, Zika and other pathogens. Infections among troops is common and can require costly, time-consuming medical leave and hospitalizations. Effective new vaccines can be pivotal in supporting healthier troops and better-operating units.
The article notes that PaxVax, a U.S.-based pharmaceutical company, is working on its own chikungunya vaccine but will work with the Walter Reed Army Institute of Research (WRAIR) to carry out its next human clinical trial, according to John Smith, chief scientific officer at PaxVax. Smith credited WRAIR with providing “significant funding to further this vaccine effort.”
“It takes all of these activities working in concert to efficiently develop new vaccines,” Smith said. “PaxVax very much appreciates the expertise that has been made available from each of these activities, and has a high level of confidence that effective vaccines will result from the close interaction that has been possible in this partnership.”